Next-Generation Imaging

Latest News

FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC
FDA grants fast track designation to 67Cu-SAR-bisPSMA for mCRPC

February 19th 2025

The designation is supported by preliminary data from the ongoing phase 1/2a SECuRE trial.

Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
PSMA staging is linked with higher rates of ADT, ARPI utilization in prostate cancer

February 18th 2025

Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer
Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer

February 11th 2025

Key FDA decisions urologists can expect in the first half of 2025
Key FDA decisions urologists can expect in the first half of 2025

January 28th 2025

FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer

January 24th 2025

Video Series
Video Interviews
Podcasts

More News

© 2025 MJH Life Sciences

All rights reserved.